News Breaks |
|
|
| November 5, 2012 |
| 08:48 EDT |  | LGND, ONXX | Ligand Pharma should benefit significantly from Onyx drug, says Roth Capital
After Onyx (ONXX) reported $18.6M in Kyprolis sales for Q3, Roth Capital notes that Ligand (LGND) receives a 3% average royalty on Kyprolis sales. The firm believes that Kyprolis will help enable Ligand to rapidly become profitable and it maintains a $25 target and Buy rating on the stock. |
|
|
News For LGND;ONXX From The Last 14 Days Check below for free stories on LGND;ONXX the last two weeks. |
|
|
| May 15, 2013 |
| 11:06 EDT |  | LGND | Ligand Pharmaceuticals management to meet with Roth Capital
 Subscribe for More Information |
|
| May 8, 2013 |
| 16:10 EDT |  | LGND | Ligand Pharmaceuticals sees Q2 EPS 3c-5c, consensus 4c
Sees Q2 revenue $9.0M-$9.5M, consensus $9.10M. |
|
| 16:08 EDT | | LGND | Ligand Pharmaceuticals reaffirms 2013 EPS view 47c-51c, consensus 46c
Subscribe for More Information |
|
| 16:07 EDT | | LGND | Ligand Pharmaceuticals reports Q1 adjusted EPS 16c, consensus 9c
Subscribe for More Information |
|
| 08:52 EDT | | ONXX | Onyx Pharmaceuticals price target raised to $115 from $105 at Maxim
Subscribe for More Information |
|
| May 7, 2013 |
| 16:01 EDT | | ONXX | Onyx Pharmaceuticals reports Q1 EPS (47c), consensus (47c)
Reports Q1 revenue $145.5M, consensus $134.36M. |
|
|
|
|
|
